Trials of oral and topical tenofovir-based PrEP show that these strategies reduce risk of HIV inection if they are used correctly and consistently. Higher adherence is directly linked to greater levels of protection.
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!